{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:42:51Z","timestamp":1784360571364,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2020.02.015","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:18:59Z","timestamp":1583497139000},"page":"e437-e444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-4883","authenticated-orcid":false,"given":"Agrima","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.02.015_bib1","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.02.015_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.015_bib3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","article-title":"Stem cell transplant for chronic myeloid leukemia in the imatinib era","volume":"47","author":"Radich","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2020.02.015_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.02.015_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.02.015_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.clml.2020.02.015_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12185-010-0764-9","article-title":"Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era","volume":"93","author":"Muramatsu","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.02.015_bib10","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.bbmt.2010.09.003","article-title":"Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?","volume":"17","author":"Suttorp","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.02.015_bib11","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.015_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2016.08.011","article-title":"Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America","volume":"67","author":"Karalexi","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.02.015_bib14","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","article-title":"Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate","volume":"53","author":"Lakshmaiah","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.02.015_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12098-014-1492-6","article-title":"Treatment of chronic\u00a0phase chronic myeloid leukemia with imatinib","volume":"82","author":"Ganesan","year":"2015","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.clml.2020.02.015_bib16","first-page":"15","article-title":"A\u00a0retrospective study of clinical profile and long term outcome to imatinib mesylate alone in childhood chronic myeloid leukemia in chronic phase","volume":"1","year":"2017","journal-title":"Gulf J Oncolog"},{"issue":"suppl","key":"10.1016\/j.clml.2020.02.015_bib17","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1200\/jco.2009.27.15_suppl.10047","article-title":"Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: results from a tertiary care referral center in India","volume":"27","author":"Ghadyalpatil","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib18","first-page":"227","article-title":"Management of CML in the pediatric age group: imatinib mesylate or SCT","volume":"22","author":"El-Alfy","year":"2010","journal-title":"J\u00a0Egypt Natl Cancer Inst"},{"key":"10.1016\/j.clml.2020.02.015_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/08880018.2010.512949","article-title":"Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib","volume":"28","author":"Alkhatib","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.02.015_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.015_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2020.02.015_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2020.02.015_bib28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4103\/ijmr.IJMR_331_19","article-title":"Paediatric chronic myeloid leukaemia: is it really a different disease?","volume":"149","author":"Pushpam","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clml.2020.02.015_bib29","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood.V120.21.3741.3741","article-title":"The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): objectives and preliminary results","volume":"120","author":"Millot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.015_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.02.015_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-5851.123712","article-title":"Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010","volume":"34","author":"Mishra","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijmpo.ijmpo_62_17","article-title":"The biology of chronic myelogenous leukemia in childhood and young adolescents: an Indian perspective","volume":"39","author":"Chandra","year":"2018","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/archdischild-2013-303889","article-title":"Gender bias in child care and child health: global patterns","volume":"99","author":"Khera","year":"2014","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clml.2020.02.015_bib34","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.015_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2020.02.015_bib36","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/2278-330X.142961","article-title":"Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase","volume":"3","author":"Linga","year":"2014","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.clml.2020.02.015_bib38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijmpo.ijmpo_104_16","article-title":"Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric chronic myeloid leukemia chronic phase on frontline imatinib","volume":"38","author":"Ganta","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clml.2020.02.015_bib42","doi-asserted-by":"crossref","first-page":"iv105","DOI":"10.1093\/annonc\/mdp143","article-title":"Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Baccarani","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib43","author":"Pushpam"},{"key":"10.1016\/j.clml.2020.02.015_bib44","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2020.02.015_bib45","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1200\/jco.2006.24.18_suppl.6535","article-title":"High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up","volume":"24","author":"Aoki","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib46","first-page":"64","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J\u00a0Glob Oncol"},{"key":"10.1016\/j.clml.2020.02.015_bib47","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","article-title":"Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia - chronic phase","volume":"83","author":"Ganta","year":"2016","journal-title":"Indian J Pediatr"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:31Z","timestamp":1761870871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265020301129"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}